Celularity Inc. Files 8-K for Material Agreement
Ticker: CELUW · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1752828
Sentiment: neutral
Topics: material-definitive-agreement, equity-securities, corporate-action
Related Tickers: CELU
TL;DR
Celularity Inc. signed a big deal on Dec 27, 2024 - check the 8-K!
AI Summary
Celularity Inc. entered into a material definitive agreement on December 27, 2024, related to unregistered sales of equity securities. The company, formerly GX Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates a significant transaction or agreement by Celularity Inc., which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered sales of equity securities can introduce uncertainty and potential dilution, warranting a medium risk assessment.
Key Numbers
- 001-38914 — SEC File Number (Identifies the company's filing history with the SEC.)
- 831702591 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Celularity Inc. (company) — Registrant
- GX Acquisition Corp. (company) — Former Company Name
- December 27, 2024 (date) — Date of earliest event reported
- 20250103 (date) — Filing Date
FAQ
What type of material definitive agreement did Celularity Inc. enter into?
The filing indicates an entry into a material definitive agreement related to unregistered sales of equity securities.
What was Celularity Inc.'s former name?
Celularity Inc.'s former name was GX Acquisition Corp.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on December 27, 2024.
In which state is Celularity Inc. incorporated?
Celularity Inc. is incorporated in Delaware.
What is Celularity Inc.'s Standard Industrial Classification code?
Celularity Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 894 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2025-01-03 17:20:20
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share CELU The Nasdaq
- $11.50 — A Common Stock at an exercise price of $11.50 per share CELUW The Nasdaq Stock Ma
- $2.375 — 's Common Stock, at a purchase price of $2.375 per share of Common Stock and accompany
- $2.97 — ate of issuance at an exercise price of $2.97 per share and have a term of exercise e
- $3.0 m — he Private Placement are expected to be $3.0 million, before deducting estimated offer
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex4-1.htm (EX-4.1) — 113KB
- ex10-1.htm (EX-10.1) — 223KB
- ex10-2.htm (EX-10.2) — 183KB
- 0001493152-25-000294.txt ( ) — 888KB
- celu-20241227.xsd (EX-101.SCH) — 4KB
- celu-20241227_def.xml (EX-101.DEF) — 29KB
- celu-20241227_lab.xml (EX-101.LAB) — 36KB
- celu-20241227_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC . Dated: January 3, 2025 By: /s/ Robert J. Hariri Name: Robert J. Hariri, M.D., Ph.D. Title: Chairman and CEO -4-